Amplyx, now a subsidiary of Pfizer Inc. @AmplyxPharma

Developing antifungal agents for the treatment of life-threatening invasive fungal infections due to Candida, Aspergillus and rare mold. amplyx.com San Diego, CA Joined May 2019

Tweets

51
Followers

154
Following

78
Likes

36

Amplyx, now a subsidiary of Pfizer Inc. @AmplyxPharma

3 years ago

On Thursday, March 25 at 11 am ET, our CEO, Ciara Kennedy, will participate in a live discussion with industry experts about the critical healthcare burden associated with #sepsis. A live Q&A will follow. Learn more:

0 0 0 0 0

Download Image

Amplyx, now a subsidiary of Pfizer Inc. @AmplyxPharma

3 years ago

Today is #WorldAspergillosisDay. Invasive aspergillosis and mucormycosis are serious mould infections – don’t forget to #ThinkFungus At Amplyx, we are proud to be developing a first-in-class antifungal with the potential to treat these life-threatening infections.

1 3 6 0 0

Download Image

Antimicrobials Working Group @AWG_News

3 years ago

Incoming AWG Chair, @CiaraKennedy4, President and CEO of @AmplyxPharma, highlights the coalitions priorities in 2021 and beyond:

0 4 2 0 0

Download Image

Antimicrobials Working Group @AWG_News

3 years ago

AWG has appointed @CiaraKennedy4, President and CEO of @AmplyxPharma as the new Chair of AWG. Dr. Kennedy replaces @EvanLohMD, CEO of @ParatekPharma, who has completed his two-year term as Chairman. bit.ly/2MyRutF

1 1 2 0 0

Amplyx, now a subsidiary of Pfizer Inc. @AmplyxPharma

4 years ago

bioworld.com/articles/49833…

0 0 0 0 0

Antimicrobials Working Group @AWG_News

4 years ago

.@endpts shares positive topline data from @AmplyxPharma's Phase 2 trial of fosmangepix, an antifungal with the potential to treat patients with life-threatening #Candida infections. The Phase 3 trial is likely to commence in 2021. Learn more: bit.ly/2CX42pV

0 3 3 0 0

Amplyx, now a subsidiary of Pfizer Inc. @AmplyxPharma

4 years ago

We're pleased to announce positive top-line data following the completion of our Phase 2 clinical trial of #Fosmanogepix, a novel antifungal therapy in development for patients with invasive fungal infections. Learn more: amplyx.com/amplyx-announc…

0 1 5 0 0

Download Image

Amplyx, now a subsidiary of Pfizer Inc. @AmplyxPharma

4 years ago

We announced the closure of a Series C financing to advance clinical development of our novel product candidates for the treatment of life-threatening diseases affecting patients with compromised immune systems. Learn more: amplyx.com/amplyx-pharmac…

0 1 7 0 0

Download Image

Amplyx, now a subsidiary of Pfizer Inc. @AmplyxPharma

4 years ago

COVID-19 and fungal superinfections could lead to a deadly, perfect storm. Read more from Ciara Kennedy, Ph.D., President & CEO, Amplyx in @Xconomy xconomy.com/san-diego/2020…

0 4 7 0 0

Download Gif

Xconomy @Xconomy

4 years ago

Emerging reports suggest as many as 1/3 of patients with severe COVID-19 infection may also be battling invasive aspergillosis, a deadly fungal superinfection caused by Aspergillus mold, says @AmplyxPharma CEO Ciara Kennedy xconomy.com/san-diego/2020…

0 2 5 0 0

Antimicrobials Working Group @AWG_News

4 years ago

.@AmplyxPharma to Participate in Antifungal Panel at Maxim Group's Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector bit.ly/2WelwnW

0 1 1 0 0

Antimicrobials Working Group @AWG_News

4 years ago

.@AmplyxPharma, @CidaraThera, and @scynexis will participate in panel discussions as part of Maxim Group's Infectious Disease Virtual Conference, highlighting innovation in the #InfectiousDisease sector and need for new anti-infectives to combat #AMR. RSVP bit.ly/3eUHogy

0 2 2 0 0

Pew Health @pewhealth

4 years ago

Our annual update on #antibiotics in clinical development is here. Right now, there are too few antibiotics in development—but more are needed. Full findings: pew.org/2K8McAQ

1 2 1 0 0

Download Image

Pew Health @pewhealth

4 years ago

The US needs to be equipped to combat ongoing and future public health emergencies, such as superbugs. You can help make a difference: #COVID19 pew.org/2VeDaqV

0 3 1 0 0

MRC Centre for Medical Mycology @MRCcmm

4 years ago

COVID-19 and ASPERGILLUS: Invasive pulmonary aspergillosis is a known complication of severe influenza, and discussions are emerging now on potential co-infection with COVID-19. @MRCcmm is summarizing the current knowledge at exeter.ac.uk/medicalmycolog… #covidANDaspergillosis

2 26 42 0 1

Download Image

Amplyx, now a subsidiary of Pfizer Inc. @AmplyxPharma

4 years ago

Continued development of innovative antimicrobials is critical, now more than ever. Lack of effective therapies increase the need for ventilators and increase mortality. Keep DISARM in #COVID relief bill future needs @GOPLeader @SpeakerPelosi @AWG_News @ScottGottliebMD

0 1 3 0 0

Antimicrobials Working Group @AWG_News

4 years ago

During the 2009 H1N1 pandemic, 29% of people with fatal pandemic #influenza were found to have bacterial co-infections. The development and use of novel #antimicrobials is critical to our ability to save lives during a global pandemic.

1 4 15 0 0

Battle Superbugs ☮️ @battlesuperbugs

4 years ago

This is pretty sobering. The "they" is oncologists: "Ninety-five percent said they worry about the impact of superbugs on the future of cancer treatments. Nearly half of those surveyed—46 percent—said they think chemotherapy will soon be unviable." ow.ly/6Rqw50yK4VG

1 20 33 0 1

Working to Fight AMR @WeFightAMR

4 years ago

It’s not just #coronavirus. “If there’s one infectious disease issue that we need to worry about, it’s #antibioticresistance.” Join the fight with #WTFAMR. montrealgazette.com/opinion/column…

0 2 4 0 0

Amplyx, now a subsidiary of Pfizer Inc. @AmplyxPharma

4 years ago

In honor of world #rarediseaseday, we are raising awareness of #BKV associated diseases that are devastating to transplant. At Amplyx, we are proud to be working on treatments for these patients who have unmet medical needs. #RDD2020